The high‐level use of psychotropic medicines, particularly antipsychotics, for the treatment of behavioural and psychological symptoms of dementia (BPSD) in residential aged care facilities (RACFs) is widely reported. The current estimates of the prevalence of psychotropic medicines in such facilities are high: 44% in the UK,1 61% in Australia2 and over 60% in the United States.3 Psychotropic medicines are recommended not to be used first‐line for the management of BPSD, and among residents with dementia are associated with significant adverse outcomes.3, 4 However, the use of these medicines remains high. They are often used outside of approved indications, for longer than recommended or at higher doses.
|Number of pages||2|
|Journal||International Journal of Pharmacy Practice|
|Early online date||6 Sep 2019|
|Publication status||Published - Oct 2019|